HOME >> MEDICINE >> NEWS
FDA approves Pfizer's Lyrica for the treatment of the two most common forms of neuropathic pain

NEW YORK, December 31, 2004 - Pfizer Inc said today that it has received approval from the U.S. Food and Drug Administration (FDA) to market LyricaTM (pregabalin capsules) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). Lyrica is the first FDA-approved treatment for both of these neuropathic pain states, which are distinctly different from arthritis or musculoskeletal pain.

Developed by Pfizer, Lyrica has a newly defined mechanism of action. Lyrica will be available to physicians and patients in the near future.

"Lyrica is an important new therapy for millions of people suffering from the two most common neuropathic pain conditions as it provides rapid and sustained pain relief," said Dr. Joseph Feczko, president of Worldwide Development at Pfizer. "Lyrica also represents a major achievement in Pfizer's research program and confirms our leadership in bringing life-changing medicines to patients."

Neuropathic pain, one of the most debilitating forms of pain, is caused by nerve damage that can result from underlying conditions, such as diabetes or shingles. Nearly half of the 18 million Americans with diabetes will develop some form of diabetic neuropathy over the course of their disease and about one in six diabetes patients will experience painful diabetic neuropathy. The pain of DPN is often described as burning, tingling, sharp, stabbing, or pins and needles in the feet, legs, hands or arms.

PHN is a complication of shingles, a painful outbreak of rash or blisters on the skin caused by a reactivation of the same virus that causes chicken pox. Each year, about 150,000 Americans develop PHN, which is often characterized as constant stabbing, burning, or electric shock-like sensation.

The efficacy of Lyrica was established in six double-blind, placebo-controlled trials, three involving patients with DPN and three involving patients with
'"/>

Contact: Rebecca Hamm
212-733-8811
Burson-Marsteller
7-Jan-2005


Page: 1 2

Related medicine news :

1. FDA approves Enablex for treatment of overactive bladder
2. FDA approves Fosrenol(R) in end-stage renal disease (ESRD) patients
3. FDA approves Adderall XR (R) to treat ADHD in adults
4. FDA approves EPZICOM
5. FDA approves new labelling for Seroquel in bioplar mania
6. FDA approves Enbrel to treat psoriasis
7. FDA approves Climara Pro to treat menopause symptoms
8. FDA approves new approach to schizophrenia treatment
9. FDA approves new HIV protease inhibitor, Lexiva (TM)
10. FDA approves Wellbutrin XL(TM)
11. FDA approves Baxters ADVATE for the treatment of hemophilia A

Post Your Comments:
(Date:10/31/2014)... October 31, 2014 At the start ... families narrowly escaping carbon monoxide poisoning in their homes. ... weeks away, one family-owned, Missouri-based heating and cooling company ... making sure families start the home heating season with ... secure. , Beginning Nov. 1, 2014, E and ...
(Date:10/31/2014)... -- Surgery for low back pain caused by spinal ... you live, a new report says. "Nearly 80 ... some point in their lives, and about 30 million ... spine problem," co-author Brook Martin, of the Dartmouth Institute ... college news release. In spinal stenosis, thickening of ...
(Date:10/31/2014)... DARIEN, IL – New research suggests that insomnia is ... crashes and other unintentional fatal injuries. The results underscore ... of the National Healthy Sleep Awareness Project. , Results ... in a dose-dependent manner with the number of insomnia ... were 2.8 times more likely to die from a ...
(Date:10/31/2014)... October 31, 2014 The Suspension Revolution ... workout program was developed by Dan Long, a suspension ... as a fitness professional and life coach. The author ... having toned muscles is not impossible , The Suspension ... suspension training. Suspension training promises efficiency when it comes ...
(Date:10/31/2014)... 31, 2014 Florida Air Academy, ... girls in grades 6-12, is taking the lead ... injuries and concussions, becoming the first high school ... (Immediate Post-Concussion Assessment and Cognitive Testing) computerized assessment ... Player' lawsuit grabs the headlines, and the Centers ...
Breaking Medicine News(10 mins):Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2Health News:Florida Air Academy Tackling Concussions Head-On 2Health News:Florida Air Academy Tackling Concussions Head-On 3
(Date:10/31/2014)... Ga. , Oct. 31, 2014  Digirad Corporation ... to PDI, Inc. (Nasdaq: PDII ), a ... of Digirad,s proposal to acquire the company.  ... meaningful discussions regarding a transaction and to operate in ... its cash, or take on additional debt, on acquisitions ...
(Date:10/31/2014)... 31, 2014 Mast Therapeutics, Inc. (NYSE MKT: ... for the quarter ended September 30, 2014. ... said:  "The third quarter was productive for Mast. Consistent with ... MST-188 for sickle cell disease is on track to ... have opened 50 study sites in the U.S. and ...
(Date:10/31/2014)... , October 31, 2014 ... Corporation (NASDAQ: CELG ), Bristol-Myers Squibb Co. ... UNH ), Sanofi SA (NYSE: ... members receive these notes ahead of publication. To reserve ... . , ,-- ,Celgene Corporation Research Reports ,On October ...
Breaking Medicine Technology:Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 2Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 3Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 4Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6
Cached News: